ArticleJournal of cancer research and clinical oncology2025

Comments on the SERAPHINA study assessing the utilization, efficacy, safety, and quality of life of nab-paclitaxel in patients with advanced HER2-negative breast cancer.

No numbers read from the abstract.

Not cited yet